Related Experiment Video
Updated: Jul 13, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin withdrawal prior to invasive medical procedures: a strategy based on thromboembolic and bleeding risk
Auryan Szalat1, Gilli Erez, Eran Leitersdorf
1Department of Internal Medicine B, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. auryan@md.huji.ac.il
Insights
Physicians often discontinue aspirin before invasive procedures, especially with low thromboembolic risk. Low molecular weight heparin (LMWH) substitution is considered for higher-risk patients, warranting further clinical evaluation.
Area of Science:
- Internal Medicine
- Cardiology
- Clinical Pharmacology
Background:
- Managing aspirin therapy before invasive procedures presents a clinical challenge due to balancing bleeding and thromboembolic risks.
- Lack of evidence-based guidelines complicates decisions on aspirin continuation or withdrawal.
Purpose of the Study:
- To evaluate internal medicine physicians' perspectives on aspirin management prior to invasive procedures.
- To understand physician decision-making regarding aspirin withdrawal, continuation, or substitution with low molecular weight heparin (LMWH).
Main Methods:
- A survey involving nine hypothetical clinical scenarios with varying bleeding and thromboembolic risks was administered.
- Physicians were interviewed and asked to choose between discontinuing aspirin, continuing aspirin, or substituting LMWH for aspirin.
Main Results:
- For low thromboembolic risk patients, 77-97% of physicians discontinued aspirin based on bleeding risk.
- For intermediate and high thromboembolic risk patients, physicians were more likely to continue aspirin or substitute with LMWH, particularly for higher bleeding risk procedures.
- LMWH substitution was recommended by 18-57% of physicians for high thromboembolic risk patients, depending on bleeding risk.
Conclusions:
- Physician decisions on aspirin management vary based on patient thromboembolic and procedural bleeding risks.
- The findings suggest a potential role for LMWH as an alternative to aspirin in specific high-risk scenarios.
- Further controlled clinical studies are recommended to validate the use of LMWH in place of aspirin.
Background:
The management of aspirin therapy before an invasive procedure poses a frequent clinical dilemma due to uncertainty regarding bleeding versus thromboembolic risks associated with continuation or withdrawal of the drug. There are no evidence-based data to refer to.
Objectives:
To assess the opinions of internal medicine physicians regarding aspirin therapy prior to an invasive procedure.
Methods:
A questionnaire presenting nine hypothetical cases with different combinations of bleeding and thromboembolic risk was given to physicians in an internal medicine division during a personal interview. For each case the participants had to choose between withdrawal of aspirin prior to an invasive procedure, continuation of aspirin, or substitution of low molecular weight heparin for aspirin.
Results:
Sixty-one physicians participated in the survey. For a patient with low thromboembolic risk, 77% (95% confidence interval 65.3-86.3%), 95% (87.2-98.7%) and 97% (89.6-99.5%) of physicians elected to discontinue aspirin prior to a low, intermediate or high bleeding risk procedure, respectively. For intermediate risk patients, 23% (95% CI 13.7-34.7%), 59% (46.4-70.8%) and 74% (61.7-83.6%) would discontinue aspirin prior to a low, intermediate or high risk procedure, and 5% (95% CI 1.3-12.8%), 23% (13.7-34.7%) and 18% (9.9-29.2%) would substitute LMWH for aspirin. For a patient with high thromboembolic risk, 1.6% (95% CI 0.08-7.8%), 11.5% (5.2-21.4%) and 18% (9.9-29.2%) recommended discontinuing aspirin prior to a low, intermediate or high risk procedure, respectively. In these situations, 18% (95% CI 9.9-29.2%), 53% (40.0-64.7%) and 57% (44.8-69.3%), respectively, would substitute LMWH for aspirin.
Conclusions:
The results of the current investigation may help practicing physicians to decide whether to discontinue aspirin therapy prior to invasive procedures. The possible use of LMWH to replace aspirin as suggested here should be further evaluated in a controlled clinical study.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...